Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Breast Tumors Detected Between Mammograms More Likely to Be Aggressive

By MedImaging International staff writers
Posted on 25 May 2011
Breast cancers that are first identifiable in the interval between screening mammograms are more likely to be aggressive, fast-growing tumors according to new findings.

The study's findings were published online May 3, 2011, in the Journal of the [US] National Cancer Institute. Other studies have shown that cancers diagnosed between mammograms, known as interval cancers, tend to have a worse prognosis than those detected during routine screening. This study examined the difference between "true" interval tumors--those not detectable on the earlier mammogram--and "missed" interval tumors--those not detected on the previous mammogram due to technical errors or misinterpretation.

The authors, Anna M. Chiarelli, PhD, from Cancer Care Ontario (Toronto, Canada), and colleagues, analyzed data from the Ontario Breast Screening Program for 288 women with true interval cancers and 87 women with missed interval cancers. Both kinds of interval tumors were compared to screen-detected tumors in 450 women who were similar in terms of age, location of the screening center, and length of time since their last mammogram.

As predicted, the true and missed interval tumors were of higher stage and grade than screen-detected cancers. However, true interval cancers were also more likely to be estrogen receptor-negative and progesterone receptor-negative, to have a high mitotic index, and to have a less common histology.

The investigators concluded that the findings suggest "a need for further advancement in imaging technologies to detect certain types of breast carcinomas and different approaches for early detection of fast-growing tumors."

Related Links:
Cancer Care Ontario



Digital Color Doppler Ultrasound System
MS22Plus
X-ray Diagnostic System
FDX Visionary-A
Mammography System (Analog)
MAM VENUS
Pocket Fetal Doppler
CONTEC10C/CL

Channels

Nuclear Medicine

view channel
Image: This artistic representation illustrates how the drug candidate NECT-224 works in the human body (Photo courtesy of HZDR/A. Gruetzner)

Radiopharmaceutical Molecule Marker to Improve Choice of Bladder Cancer Therapies

Targeted cancer therapies only work when tumor cells express the specific molecular structures they are designed to attack. In urothelial carcinoma, a common form of bladder cancer, the cell surface protein... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.